Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: losartan potassium Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

NCT02049307
View directory record Official record
Conditions
Inflammation, Fibrosis
Interventions
Losartan 100mg daily, Matching placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Sex Differences in the Dilatory Response of Compound 21

NCT05576155
View directory record Official record
Conditions
Sex Differences
Interventions
Compound 21, Compound 21 + losartan
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

NCT02263729
View directory record Official record
Conditions
Hamstring Injury
Interventions
Losartan, Placebo
Drug
Lead sponsor
James J. Irrgang
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

NCT00879879
View directory record Official record
Conditions
Precancerous Condition
Interventions
losartan
Drug
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

NCT01149473
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

NCT00931710
View directory record Official record
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2Phase 3 Interventional

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

NCT02410005
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Calcitriol, Losartan
Dietary Supplement · Drug
Lead sponsor
Weill Cornell Medical College in Qatar
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions
Olmesartan medoxomil, Losartan potassium, Atenolol
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2005 · Synced Oct 2, 2026, 4:12 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 2, 2026, 4:12 AM EDT
Not listed Phase 1Phase 2 Interventional

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

NCT04815902
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
40 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 2, 2026, 4:12 AM EDT
Not listed No phase listed Observational

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

NCT04743063
View directory record Official record
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

NCT01806324
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
HL040XC, Losartan + Atorvastatin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
19 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 2, 2026, 4:12 AM EDT
Withdrawn Phase 3 Interventional

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

NCT01361087
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Blood draw
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Not Requiring Hospitalization

NCT04311177
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 2 Interventional Results available

Losartan for the Treatment of Pediatric NAFLD

NCT03467217
View directory record Official record
Conditions
NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Losartan potassium, Placebo losartan capsule
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vascular Dysfunction in Hypertensive Postmenopausal Women

NCT03371823
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Normotensive, Hypertensives
Other · Drug
Lead sponsor
University of Delaware
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available

Cardiomyopathy in DMD: Lisinopril vs. Losartan

NCT01982695
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
Interventions
Losartan, Lisinopril
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Davis, California • Kansas City, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 2, 2026, 4:12 AM EDT
Completed Early Phase 1 Interventional Results available

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Losartan Potassium, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 2, 2026, 4:12 AM EDT